Skip to search formSkip to main contentSkip to account menu

DEBIO-025

National Institutes of Health

Related topics

Related topics

1 relation
alisporivir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Update on alisporivir in treatment of viral hepatitis C
Introduction: There are two classes of anti-hepatitis C virus (HCV) agents currently in development: direct-acting antivirals… 
Review
2012
Review
2012
Treatment of patients with genotype 3 chronic hepatitis C‐ current and future therapies
Genotype 3 is a common type of HCV infection, and standard therapy using pegylated interferon (PEG‐IFN) and ribavirin (RBV) is… 
2009
2009
Stomach: Quadruple therapy for Helicobacter pylori eradication
  • J. Gisbert
  • Nature Reviews Gastroenterology &Hepatology
  • 2009
  • Corpus ID: 26855630
The low success rates of standard triple-therapy regimens for eradication of Helicobacter pylori infection have led to… 
2009
2009
946 PK-PD MODELING OF VIRAL KINETICS DURING TREATMENT WITH DEBIO-025 PLUS PEGYLATED INTERFERON ALPHA-2A IN TREATMENT-NAIVE HCV PATIENTS
2008
2008
Particular characteristics of the in vitro anti-hepatitis C virus activity of Debio-025, a non-immunosuppressive cyclophilin binding molecule
Review
2007
Review
2007
Cyclophilin inhibitors in hepatitis C viral infection
Cyclophilins (Cyps) are proteins that are ubiquitously present with peptidyl-prolyl cis-trans isomerase activity and play an… 
2007
2007
[88] VIRAL KINETICS DURING 14-DAY TREATMENT WITH DEBIO-025 DEMONSTRATE EFFICIENT BLOCKING OF VIRAL REPLICATION IN DIFFERENT HCV GENOTYPES WITHOUT SIGNS OF EMERGING VIRAL RESISTANCE
2006
2006
406 Debio-025 is a promising new drug for the treatment of chronic hepatitis C
2005
2005
Debio-025, a novel non-immunosuppressive cyclosporine analog with potent anti-human immunodeficiency virus type I activity: Pharmacological properties and mode of action
Reference LCBP-ARTICLE-2005-005View record in Web of Science Record created on 2006-02-09, modified on 2016-08-08 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)